Teamwork Financial Advisors LLC Sells 537 Shares of Eli Lilly and Company (NYSE:LLY)

Teamwork Financial Advisors LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 61.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 334 shares of the company’s stock after selling 537 shares during the period. Teamwork Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $276,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. FPC Investment Advisory Inc. raised its position in shares of Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after buying an additional 43 shares in the last quarter. Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company in the 4th quarter worth about $43,000. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $48,000. Compass Financial Services Inc purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $50,000. Finally, Capital A Wealth Management LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $63,000. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Up 0.5%

Shares of Eli Lilly and Company stock opened at $750.94 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a market cap of $711.69 billion, a P/E ratio of 64.13, a PEG ratio of 1.40 and a beta of 0.48. The company’s fifty day simple moving average is $773.82 and its two-hundred day simple moving average is $799.64.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the company earned $2.58 earnings per share. Eli Lilly and Company’s quarterly revenue was up 45.2% on a year-over-year basis. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.80%. Eli Lilly and Company’s payout ratio is 48.82%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on LLY. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Guggenheim restated a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 target price for the company. Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, May 30th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.